Drug and environmental factors associated with adverse pregnancy outcomes: Part I: Antiepileptic drugs, contraceptives, smoking, and folate

Annals of Pharmacotherapy

Volumn 32, Issue 7-8, 1998, Pages 802-817

  Lewis, Dale P ^a,b   Van Dyke, Don C ^c   Stumbo, Phyllis J ^a   Berg, Mary J ^a  

^a UNIVERSITY OF IOWA   (United States)

^b St Luke's Hospital   (United States)

^c UNIVERSITY OF IOWA   (United States)

Author keywords

Antiepileptic drugs; Contraceptives; Folate; Neural tube defect; Smoking

Indexed keywords

ANTICONVULSIVE AGENT; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CLOMIFENE; CLONAZEPAM; COLCHICINE; COTRIMOXAZOLE; CYCLOSERINE; DESOGESTREL; DIAZEPAM; EPOXIDE; ETHINYLESTRADIOL; FELBAMATE; FOLIC ACID; LAMOTRIGINE; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; METHOTREXATE; ORAL CONTRACEPTIVE AGENT; OXAZEPAM; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; SALAZOSULFAPYRIDINE; STIRIPENTOL; TRIAMTERENE; TRIMETHOPRIM; UNINDEXED DRUG; VALPROIC ACID;

BIRTH DEFECT; DRUG INDUCED DISEASE; DRUG METABOLISM; EPILEPSY; FOLIC ACID DEFICIENCY; GENETIC SUSCEPTIBILITY; HUMAN; NEURAL TUBE DEFECT; NONHUMAN; PREGNANCY COMPLICATION; PRIORITY JOURNAL; RAT; REVIEW; SMOKING; TERATOGENICITY;

EID: 0031852410     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.17297     Document Type: Review

References (171)

1. Meadow SR. Anticonvulsant drugs and congenital abnormalities (letter). Lancet 1968;2:1296.
2. Hanson JW, Smith DW. The fetal hydantoin syndrome. J Pediatr 1975; 87:285-90.
3. Hanson JW, Myrianthopoulos NC, Harvey MAS, Smith DW. Risks to the offspring of women treated with hydantoin anticonvulsants, with emphasis on the fetal hydantoin syndrome. J Pediatr 1976;89:662-8.
4. Czeizel AE, Bod M, Halasz P. Evaluation of anticonvulsant drugs during pregnancy in a population-based Hungarian study. Eur J Epidemiol 1992;8:122-7.
5. Dansky LV, Finnell RH. Parental epilepsy, anticonvulsant drugs, and reproductive outcome: epidemiologic and experimental findings spanning three decades. II human studies. Reprod Toxicol 1991;5:301-35.
6. Lewis DP, Van Dyke DC, Willhite LA, Stumbo PJ, Berg MJ. Phenytoin-folic acid interaction. Ann Pharmacother 1995;29:726-35.
7. Dansky LV, Rosenblatt DS, Andermann E. Mechanisms of teratogenesis: folic acid and antiepileptic therapy. Neurology 1992;42(suppl 5):32-42.
8. Hibbard BM. Folates and fetal development. Br J Obstet Gynaecol 1993; 100:307-9.
9. Lewis CA, Pancharuniti N, Sauberlich HE. Plasma folate adequacy as determined by homocysteine level. Ann N Y Acad Sci 1992;669:360-2.
10. Daly LE, Kirke PN, Molloy A, Weir DG, Scott JM. Folate levels and neural tube defects: implications for prevention. JAMA 1995;274:1698-702.
11. 12, pantothenic acid, biotin, and choline. Washington, DC: National Academy Press, 1998.
12. McPartlin J, Halligan A, Scott JM, Darling M, Weir DG. Accelerated folate breakdown in pregnancy. Lancet 1993;341:148-9.
13. O'Keefe CA, Bailey LB, Thomas EA, Hofler SA, Davis BA, Cerda JJ, et al. Controlled dietary folate affects folate status in nonpregnant women. J Nutr 1995;125:2717-25.
14. Jacob RA, Wu M, Henning SM, Swendseid ME. Homocysteine increases as folate decreases in plasma of healthy men during short-term dietary folate and methyl group restriction. J Nutr 1994;124:1072-80.
15. Selhub J, Jacques PF, Wilson PWF, Rush D, Rosenberg IH. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 1993;270:2693-8.
16. Oakley GP, Adams MJ, Dickinson CM. More folic acid for everyone, now. J Nutr 1996;126(suppl):751S-5S.
17. 12 deficiency in pregnancy and in the neonatal period. Clin Perinatol 1984;11:433-59.
18. Bruinse HW, Berg HVD, Haspels AA. Maternal serum folacin levels during and after normal pregnancy. Eur J Obstet Gynec Reprod Bio 1985;20:153-8.
19. Rose NC, Mennuti MT. Periconceptional folic acid supplementation as a social intervention. Semin Perinatol 1995;19:243-54.
20. Scott JM, Kirke PN, Weir DG. The role of nutrition in neural tube defects. Annu Rev Nutr 1990;10:277-95.
21. Van Allen MI, Kalousek DK, Chernoff GF, Juriloff D, Harris M, McGillivray BC, et al. Evidence for multi-site closure of the neural tube in humans. Am J Med Genet 1993;47:723-43.
22. Golden JA, Chemoff GF. Multiple sites of anterior neural tube closure in humans: evidence from anterior neural tube defects (anencephaly). Pediatrics 1995;95:506-10.
23. Yen IH, Khoury MJ, Erickson JD, James LM, Waters GD, Berry RJ. The changing epidemiology of neural tube defects: United States, 1968-1989. Am J Dis Child 1992;146:857-61.
24. Slattery ML, Janerich DT. The epidemiology of neural tube defects: a review of dietary intake and related factors as etiologic agents. Am J Epidemiol 1991;133:526-40.
25. Velie EM, Shaw GM. Impact of prenatal diagnosis and elective termination on prevalence and risk estimates of neural tube defects in California, 1989-1991. Am J Epidemiol 1996;144:473-9.
26. Roberts HE, Moore CA, Cragan JD, Fernhoff PM, Khoury MJ. Impact of prenatal diagnosis on the birth prevalence of neural tube defects, Atlanta, 1990-1991. Pediatrics 1995;96:880-3.
27. Surveillance for anencephaly and spina bifida and the impact of prenatal diagnosis - United States, 1985-1994. MMWR Morb Mortal Wkly Rep 1995;44:1-13.
28. Graf W, Pippenger CE. Glutathione peroxidase deficiency in families with neural tube defects (abstract). Ann Neurol 1993;34:476-7.
29. Harris JA, Shaw GM. Neural tube defects - why are rates high among populations of Mexican descent? Environ Health Perspect 1995;103 (suppl 6):163-4.
30. Canfield MA, Annegers JF, Brender JD, Cooper SP, Greenberg F. Hispanic origin and neural tube defects in Houston/Harris County, Texas: 1. Descriptive epidemiology. Am J Epidemiol 1996;143:1-11.
31. Canfield MA, Annegers JF, Brender JD, Cooper SP, Greenberg F. Hispanic origin and neural tube defects in Houston/Harris County, Texas: 2. Risk factors. Am J Epidemiol 1996;143:12-24.
32. Blatter BM, Roeleveld N, Zielhuis GA, Mullaart RA, Gabreels FJM. Spina bifida and parental occupation. Epidemiology 1996;7:188-93.
33. Sever LE. Looking for causes of neural tube defects: where does the environment fit in? Environ Health Perspect 1995;103(suppl 6):165-71.
34. Matte TD, Mulinare J, Erickson JD. Case-control study of congenital defects and parental employment in health care. Am J Ind Med 1993;24: 11-23.
35. Milunsky A, Ulcickas M, Rothman KJ, Willett W, Jick SS, Jick H. Maternal heat exposure and neural tube defects. JAMA 1992;268:882-5.
36. Bound JP, Harvey PW, Francis BJ, Awwad F, Gatrell AC. Involvement of deprivation and environmental lead in neural tube defects: a matched case-control study. Arch Dis Child 1997;76:107-12.
37. Rose NC, Mennuti MT. Periconceptional folate supplementation and neural tube defects. Clin Obstet Gynecol 1994;37:605-20.
38. Becerra JE, Khoury MJ, Cordero JF, Erickson JD. Diabetes mellitus during pregnancy and the risks for specific birth defects: a population-based case control study. Pediatrics 1990;85:1-9.
39. Parkinson CE, Tan JCY, Gal I. Vitamin A concentration in amniotic fluid and maternal serum related to neural-tube defects. Br J Obstet Gynaecol 1982;89:935-9.
40. Gal I, Sharman IM, Pryse-Davies J. Vitamin A in relation to human congenital malformations. Adv Teratol 1972;5:143-59.
41. Rothman KJ, Moore LL, Singer MR, Nguyen UDT, Mannino S, Milunsky A. Teratogenicity of high vitamin A intake. N Engl J Med 1995;333: 1369-73.
42. 12 and transcobalamins in neural tube defects. Clin Genet 1988;33:441-8.
43. 12 are independent risk factors for neural tube defects. Q J Med 1993;86:703-8.
44. 12 and anencephaly (letter). Lancet 1980;1:880.
45. Guvenc H, Karatas F, Guvenc M, Kunc S, Aygun AD, Bektas S. Low levels of selenium in mothers and their newborns in pregnancies with a neural tube defect. Pediatrics 1995;95:879-82.
46. Sato M, Shirota M, Nagao T. Pantothenic acid decreases valproic acid-induced neural tube defects in mice (I). Teratology 1995;52:143-8.
47. Watkins ML, Scanlon KS, Mulinare J, Khoury MJ. Is maternal obesity a risk factor for anencephaly and spina bifida? Epidemiology 1996;7:507-12.
48. Shaw GM, Velie EM, Schaffer D. Risk of neural tube defect-affected pregnancies among obese women. JAMA 1996;275:1093-6.
49. Werler MM, Louik C, Shapiro S, Mitchell AA. Prepregnant weight in relation to risk of neural tube defects. JAMA 1996;275:1089-92.
50. Kalucy M, Bower C, Stanley F, Burton P. Survival of infants with neural tube defects in Western Australia 1966-1990. Paediatr Perinat Epidemiol 1994;8:334-51.
51. Hunt GM. Open spina bifida: outcome for a complete cohort treated unselectively and followed into adulthood. Dev Med Child Neurol 1990; 32:108-18.
52. 12 concentrations in pregnancies associated with neural tube defects. Arch Dis Child 1985;60:660-5.
53. Mills JL, Tuomilehto J, Yu KF, Colman N, Blaner WS, Koskela P, et al. Maternal vitamin levels during pregnancies producing infants with neural tube defects. J Pediatr 1992;120:863-71.
54. Yates JRW, Ferguson-Smith MA, Shenkin A, Guzman-Rodriguez R, White M, Clark BJ. Is disordered folate metabolism the basis for the genetic predisposition to neural tube defects? Clin Genet 1987;31:279-87.
55. Wild J, Seller MJ, Schorah CJ, Smithells RW. Investigation of folate intake and metabolism in women who have had two pregnancies complicated by neural tube defects. Br J Obstet Gynaecol 1994;101:197-202.
56. Lucock MD, Wild J, Schorah CJ, Levene MI, Hartley R. The methylfolate axis in neural tube defects: in vitro characterisation and clinical investigation. Biochem Med Metabol Biol 1994;52:101-14.
57. Bunduki V, Dommergues M, Zittoun J, Marquet J, Muller F, Dumez Y. Maternal-fetal folate status and neural tube defects: a case control study. Biol Neonate 1995;67:154-9.
58. Davis BA, Bailey LB, Gregory JF, Toth JP, Dean J, Stevenson RE. Folic acid absorption in women with a history of pregnancy with neural tube defect. Am J Clin Nutr 1995;62:782-4.
59. Andres RL, Larrabee KD. The perinatal consequences of smoking and alcohol use. Curr Probl Obstet Gynecol Fertil 1996;19:171-204.
60. Kallen K. Maternal smoking and orofacial clefts. Cleft Palate Craniofac J 1997;34:11-6.
61. Khoury MJ, Gomez-Farias M, Mulinare J. Does maternal cigarette smoking during pregnancy cause cleft lip and palate in offspring? Am J Dis Child 1989;143:333-7.
62. 12. Am J Clin Nutr 1994;60:559-66.
63. Ortega RM, Lopez-Sobaler AM, Gonzalez-Gross MM, Redondo RM, Marzana I, Zamora MJ, et al. Influence of smoking on folate intake and blood folate concentrations in a group of elderly Spanish men. J Am Coll Nutr 1994;13:68-72.
64. Witter FR, Blake DA, Baumgardner R, Mellits ED, Niebyl JR. Folate, carotene, and smoking (letter). Am J Obstet Gynecol 1982;144:857.
65. Nakazawa Y, Chiba K, Imatoh N, Kotorii T, Sakamoto T, Ishizaki T. Serum folic acid levels and antipyrine clearance rates in smokers and non-smokers. Drug Alcohol Depend 1983;11:201-7.
66. Nakane Y, Okuma T, Takahashi R, Sato Y, Wada T, Sato T, et al. Multiinstitutional study on the teratogenicity and fetal toxicity of antiepileptic drugs: a report of a collaborative study group in Japan. Epilepsia 1980; 21:663-80.
67. Van Dyke DC, Berg MJ, Olson CH. Differences in phenytoin biotransformation and susceptibility to congenital malformations: a review. DICP Ann Pharmacother 1991;25:987-92.
68. Van Dyke DC, Hodge SE, Heide F, Hill LR. Family studies in fetal phenytoin exposure. J Pediatr 1988;113:301-6.
69. Scolnik D, Nulman I, Rovet J, Gladstone D, Czuchta D, Gardner HA, et al. Neurodevelopment of children exposed in utero to phenytoin and carbamazepine monotherapy. JAMA 1994;271:767-70.
70. Vanoverloop D, Schnell RR, Harvey EA, Holmes LB. The effects of prenatal exposure to phenytoin and other anticonvulsants on intellectual function at 4 to 8 years of age. Neurotoxicol Teratol 1992;14:329-35.
71. Finnell RH, Dansky LV. Parental epilepsy, anticonvulant drugs, and experimental findings spanning three decades. I animal studies. Reprod Toxicol 1991;5:281-99.
72. Finnell RH, Abbott LC, Taylor SM. The fetal hydantoin syndrome: answers from a mouse model. Reprod Toxicol 1989;3:127-33.
73. Tomson T, Lindbom U, Ekqvist B, Sundqvist A. Epilepsy and pregnancy: a prospective study of seizure control in relation to free and total plasma concentrations of carbamazepine and phenytoin. Epilepsia 1994; 35:122-30.
74. Tomson T, Lindbom U, Ekqvist B, Sundqvist A. Disposition of carbamazepine and phenytoin in pregnancy. Epilepsia 1994;35:131-5.
75. Lander CM, Eadie MJ. Plasma antiepileptic drug concentrations during pregnancy. Epilepsia 1991;32:257-66.
76. Yerby MS, Friel PN, McCormick K, Koerner M, Van Allen M, Leavitt AM, et al. Pharmacokinetics of anticonvulsants in pregnancy: alterations in plasma protein binding. Epilepsy Res 1990;5:223-8.
77. Dickinson RG, Hooper WD, Wood B, Lander CM, Eadie MJ. The effect of pregnancy in humans on the pharmacokinetics of stable isotope labelled phenytoin. Br J Clin Pharmacol 1989;28:17-27.
78. Buehler BA, Delimont D, Van Waes M, Finnell RH. Prenatal prediction of risk of the fetal hydantoin syndrome. N Engl J Med 1990;322: 1567-72.
79. Rivey MP, Schottelius DD, Berg MJ. Phenytoin-folic acid: a review. Drug Intell Clin Pharm 1984;18:292-301.
80. Eadie MJ, McKinnon GE, Dickinson RG, Hooper WD, Lander CM. Phenytoin metabolism during pregnancy. Eur J Clin Pharmacol 1992;43:389-92.
81. Finnell RH, Kerr BM, Van Waes M, Steward RL, Levy RH. Protection from phenytoin-induced congenital malformations by coadministration of the antiepileptic drug stiripentol in a mouse model. Epilepsia 1994; 35:141-8.
82. Billings RE. Decreased hepatic 5,10-methylenetetrahydrofolate reductase activity in mice after chronic phenytoin treatment. Mol Pharmacol 1984;25:459-66.
83. Hansen DK, Billings RE. Phenytoin teratogenicity and effects on embryonic and maternal folate metabolism. Teratology 1985;31:363-71.
84. Espinasse M, Manouvrier S, Boute O, Farriaux JP. Embryofoetopathie au valproate: une pathologie encore trop mal connue. A propos de quatre observations. Arch Pediatr 1996;3:896-9.
85. Jones KL, Lacro RV, Johnson KA, Adams J. Pattern of malformations in the children of women treated with carbamazepine during pregnancy. N Engl J Med 1989;320:1661-6.
86. Finnell RH, Nau H, Yerby MS. General principles: teratogenicity of antiepileptic drugs. In: Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic drugs. 4th ed. New York: Raven Press, 1995:209-30.
87. Rosa FW. Spina bifida in infants of women treated with carbamazepine during pregnancy. N Engl J Med 1991;324:674-7.
88. Van der pol MC, Hadders-Algra M, Huisjes HJ, Touwen BCL. Antiepileptic medication in pregnancy: late effects on the children's central nervous system development. Am J Obstet Gynecol 1991;164:121-8.
89. Ornoy A, Cohen E. Outcome of children born to epileptic mothers treated with carbamazepine during pregnancy. Arch Dis Child 1996;75:517-20.
90. Lindhout D, Hoppener RJEA, Meinardi H. Teratogenicity of antiepileptic drug combinations with special emphasis on epoxidation (of carbamazepine). Epilepsia 1984;25:77-83.
91. Finnell RH, Bennett GD, Slattery JT, Amore BM, Bajpai M, Levy RH. Effect of treatment with phenobarbital and stiripentol on carbamazepine-induced teratogenicity and reactive metabolite formation. Teratology 1995;52:324-32.
92. Smith DB, Carl GF. Interactions between folates and carbamazepine or valproate in the rat. Neurology 1982;32:965-9.
93. Calandre EP, Jorde F, Rodriguez E. Serum folate concentrations in epileptic patients treated with carbamazepine and valproate (abstract). Epilepsia 1991;32(suppl 1):75.
94. Omtzigt JGC, Los FJ, Grobbee DE, Pijpers L, Jahoda MGJ, Brandenburg H, et al. The risk of spina bifida aperta after first-trimester exposure to valproate in a prenatal cohort. Neurology 1992;42(suppl 5): 119-25.
95. Lindhout D, Omtzigt JGC, Cornel MC. Spectrum of neural-tube defects in 34 infants prenatally exposed to antiepileptic drugs. Neurology 1992; 42(suppl 5):111-8.
96. Nau H, Hauck R, Ehlers K. Valproic acid-induced neural tube defects in mouse and human: aspects of chirality, alternative drug development, pharmacokinetics and possible mechanisms. Pharmacol Toxicol 1991;69:310-21.
97. DiLiberti JH, Farndon PA, Dennis NR, Curry CJR. The fetal valproate syndrome. Am J Med Genet 1984;19:473-81.
98. Chessa L, Iannetti P. Fetal valproate syndrome (letter). Am J Med Genet 1986;24:381-2.
99. Jager-Roman E, Deichl A, Jakob S, Hartmann A, Koch S, Rating D, et al. Fetal growth, major malformations, and minor anomalies in infants born to women receiving valproic acid. J Pediatr 1986;108:997-1004.
100. Chitayat D, Farrell K, Anderson L, Hall JG. Congenital abnormalities in two sibs exposed to valproic acid in utero. Am J Med Genet 1988; 31:369-73.
101. Ardinger HH, Atkin JF, Blackston RD, Elsas LJ, Clarren SK, Livingstone S, et al. Verification of the fetal valproate syndrome phenotype. Am J Med Genet 1988;29:171-85.
102. Thisted E, Ebbesen F. Malformations, withdrawal manifestations, and hypoglycaemia after exposure to valproate in utero. Arch Dis Child 1993;69:288-91.
103. Christianson AL, Chesler N, Kromberg JGR. Fetal valproate syndrome: clinical and neuro-developmental features in two sibling pairs. Dev Med Child Neurol 1994;36:361-9.
104. Winter RM, Donnai D, Burn J, Tucker SM. Fetal valproate syndrome: is there a recognisable phenotype? J Med Genet 1987;24:692-5.
105. Koch S, Jagar-Roman E, Losche G, Nau H, Rating D, Helge H. Antiepileptic drug treatment in pregnancy: drug side effects in the neonate and neurological outcome. Acta Paediatr 1996;84:739-46.
106. Baillie TA, Sheffels PR. Valproic acid: chemistry and biotransformation. In: Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic drugs. 4th ed. New York: Raven Press, 1995:589-604.
107. Nau H, Tzimas G, Mondry M, Plum C, Spohr HL. Antiepileptic drugs alter endogenous retinoid concentrations: a possible mechanism of teratogenesis of anticonvulsant therapy. Life Sci 1995;57:53-60.
108. Wegner C, Nau H. Alteration of embryonic folate metabolism by valproic acid during organogenesis: implications for mechanism of teratogenesis. Neurology 1992;42(suppl 5):17-24.
109. Bergman U, Rosa FW, Baum C, Wiholm B, Faich GA. Effects of exposure to benzodiazepine during fetal life. Lancet 1992;340:694-6.
110. Laegreid L, Olegard R, Walstrom J, Conradi N. Teratogenic effects of benzodiazepine use during pregnancy. J Pediatr 1989;114:126-31.
111. Laegreid L, Hagberg G, Lundberg A. Neurodevelopment in late infancy after prenatal exposure to benzodiazepines - a prospective study. Neuropediatrics 1992;23:60-7.
112. Laegreid L, Kyllerman M, Hedner T, Hagberg B, Viggedahl G. Benzodiazepine amplification of valproate teratogenic effects in children of mothers with absence epilepsy. Neuropediatrics 1993;24:88-92.
113. Czeizel A, Lendvay A. In-utero exposure to benzodiazepines (letter). Lancet 1987;1:628.
114. Seip M. Growth retardation, dysmorphic facies and minor malformations following massive exposure to phenobarbitone in utero. Acta Paediatr Scand 1976;65:617-21.
115. Rudd NL, Freedom RM. A possible primidone embryopathy. J Pediatr 1979;94:835-7.
116. Krauss CM, Holmes LB, VanLang QN, Keith DA. Four siblings with similar malformations after exposure to phenytoin and primidone. J Pediatr 1984;105:750-5.
117. Waters CH, Belai Y, Gott PS, Shen P, De Giorgio CM. Outcomes of pregnancy associated with antiepileptic drugs. Arch Neurol 1994;51: 250-3.
118. Reinisch JM, Sanders SA, Mortensen EL, Rubin DB. In utero exposure to phenobarbital and intelligence deficits in adult men. JAMA 1995; 274:1518-25.
119. Smith DB, Racusen LC. Folate metabolism and the anticonvulsant efficacy of phenobarbital. Arch Neurol 1973;28:18-22.
120. Bovina C, Formiggini G, Battino M, Sassi S, Marchetti M. Changes in hepatic folylpolyglutamate pattern in phenobarbitone-treated rats. Biochem Pharmacol 1990;39:1847-51.
121. Carl GF, Gill MW, Schatz RA. Effect of chronic primidone treatment on folate-dependent one-carbon metabolism in the rat. Biochem Pharmacol 1987;36:2139-44.
122. Carl GF, Eto I, Krumdieck CL. Chronic treatment of rats with primidone causes depletion of pteroylpentaglutamates in liver. J Nutr 1987; 117:970-5.
123. Hiilesmaa VK, Teramo K, Granstrom M, Bardy AH. Serum folate concentrations during pregnancy in women with epilepsy: relation to antiepileptic drug concentrations, number of seizures, and fetal outcome. Br Med J 1983;287:577-9.
124. Lindhout D. Pharmacogenetics and drug interactions: role in antiepileptic-drug-induced teratogenesis. Neurology 1992;42(suppl 5):43-7.
125. Kerr BM, Levy RH. Inhibition of epoxide hydrolase by anticonvulsants and risk of teratogenicity (letter). Lancet 1989;1:610-1.
126. Svinarov DA, Pippenger CE. Valproic acid-carbamazepine interaction: is valproic acid a selective inhibitor of epoxide hydrolase? Ther Drug Monit 1995;17:217-20.
127. Gilman JT. Lamotrigine: an antiepileptic agent for the treatment of partial seizures. Ann Pharmacother 1995;29:144-51.
128. Sander JW, Patsalos PN. An assessment of serum and red blood cell folate concentrations in patients with epilepsy on lamotrigine therapy. Epilepsy Res 1992;13:89-92.
129. May TW, Rambeck B, Jurgens U. Serum concentrations of lamotrigine in epileptic patients: the influence of dose and comedication. Ther Drug Monit 1996;18:523-31.
130. Warner T, Patsalos PN, Prevett M, Elyas AA, Duncan JS. Lamotrigine-induced carbamazepine toxicity: an interaction with carbamazepine-10, 11-epoxide. Epilepsy Res 1992;11:147-50.
131. Graves NM. Felbamate. Ann Pharmacother 1993;27:1073-81.
132. Reidenberg P, Glue P, Banfield CR, Colucci RD, Meehan JW, Radwanski E, et al. Effects of felbamate on the pharmacokinetics of phenobarbital. Clin Pharmacol Ther 1995;58:279-87.
133. Albani F, Theodore WH, Washington P, Devinsky O, Bromfield E, Porter RJ, et al. Effect of felbamate on plasma levels of carbamazepine and its metabolites. Epilepsia 1991;32:130-2.
134. Andrews CO, Fischer JH. Gabapentin: a new agent for the management of epilepsy. Ann Pharmacother 1994;28:1188-96.
135. Ben-Menachem E. Vigabatrin: chemistry, absorption, distribution, and elimination. In: Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic drugs. 4th ed. New York: Raven Press, 1995:915-23.
136. Strickler SM, Miller MA, Andermann E, Dansky LV, Seni M, Spielberg SP. Genetic predisposition to phenytoin-induced birth defects. Lancet 1985;2:746-9.
137. Finnell RH, Buehler BA, Kerr BM, Ager PL, Levy RH. Clinical and experimental studies linking oxidative metabolism to phenytoin-induced teratogenesis. Neurology 1992;42(suppl 5):25-31.
138. Bustamante SA, Stumpff LC. Fetal hydantoin syndrome in triplets: a unique experiment of nature. Am J Dis Child 1978;132:978-9.
139. Phelan MC, Pellock JM, Nance WE. Discordant expression of fetal hydantoin syndrome in heteropaternal dizygotic twins. N Engl J Med 1982;307:99-101.
140. Hill L, Murphy M, McDowall M, Paul AH. Maternal drug histories and congenital malformations: limb reduction defects and oral clefts. J Epidemiol Community Health 1988;42:1-7.
141. King PB, Lie RT, Irgens LM. Spina bifida and cleft lip among newborns of Norwegian women with epilepsy: changes related to the use of anticonvulsants. Am J Public Health 1996;86:1454-6.
142. Dansky LV, Andermann E, Rosenblatt D, Sherwin AL, Andermann F. Anticonvulsants, folate levels, and pregnancy outcome: a prospective study. Ann Neurol 1987;21:176-82.
143. 12 in long-term anticonvulsant therapy. Mt Sinai J Med 1983;50:517-21.
144. Ogawa Y, Kaneko S, Otani K, Fukushima Y. Serum folic acid levels in epileptic mothers and their relationship to congenital malformations. Epilepsy Res 1991;8:75-8.
145. 12 metabolism. Can Med Assoc J 1982;126:244-7.
146. 12, C and folacin. J Nurse Midwifery 1984;29:386-90.
147. Lambie DG, Johnson RH. Drugs and folate metabolism. Drugs 1985; 30:145-55.
148. Martinez O, Roe DA. Effect of oral contraceptives on blood folate levels in pregnancy. Am J Obstet Gynecol 1977;128:255-61.
149. Steegers-Theunissen RPM, Van Rossum JM, Steegers EAP, Thomas CMG, Eskes TKAB. Sub-50 oral contraceptives affect folate kinetics. Gynecol Obstet Invest 1993;36:230-3.
150. Cuckle HS, Wald NJ. Evidence against oral contraceptives as a cause of neural tube defects. Br J Obstet Gynaecol 1982;89:547-9.
151. Vessey M, Meisler L, Flavel R, Yeates D. Outcome of pregnancy in women using different methods of contraception. Br J Obstet Gynaecol 1979;86:548-56.
152. Kasan PN, Andrews J. Oral contraception and congenital abnormalities. Br J Obstet Gynaecol 1980;87:545-51.
153. Royal College of General Practitioners' Oral Contraception Study. The outcome of pregnancy in former oral contraceptive users. Br J Obstet Gynaecol 1976;83:608-16.
154. Bracken MB, Holford TR, White C, Kelsey JL. Role of oral contraception in congenital malformations of offspring. Int J Epidemiol 1978;7: 309-17.
155. Mattson RH, Cramer JA, Darney PD, Naftolin F. Use of oral contraceptives by women with epilepsy. JAMA 1986;256:238-40.
156. Amatayakul K, Sivasomboon B, Thanangkul O. Vitamin and trace mineral metabolism in medroxyprogesterone acetate users. Contraception 1978;18:253-69.
157. Sandler B. Anencephaly and ovulation stimulation (letter). Lancet 1973;2:379.
158. Field B, Kerr C. Ovulation stimulation and defects of neural-tube closure (letter). Lancet 1974;2:1511.
159. Singh M, Singhi S. Possible relationship between clomiphene and neural tube defects (letter). J Pediatr 1978;93:152.
160. Dyson JL, Kohler HG. Anencephaly and ovulation stimulation (letter). Lancet 1973;1:1256-7.
161. Ahlgren M, Kallen B, Rannevik G. Outcome of pregnancy after clomiphene therapy. Acta Obstet Gynecol Scand 1976;55:371-5.
162. Cuckle H, Wald N. Ovulation induction and neural tube defects (letter). Lancet 1989;2:1281.
163. Cornel MC, Ten Kate LP, Dukes MNG, Dejong-VD Berg LTW, Meyboom RHB, Garbis H, et al. Ovulation induction and neural tube defects (letter). Lancet 1989;1:1386.
164. Czeizel A. Ovulation induction and neural tube defects (letter). Lancet 1989;2:167.
165. Karabacak RO, Korur C, Celiloglu M. Ovulation induction and neural tube defects (letter). Lancet 1989;2:1391-2.
166. Goldfarb AF, Morales A, Rakoff AE, Protos P. Critical review of 160 clomiphene-related pregnancies. Obstet Gynecol 1968;31:342-5.
167. Kurachi K, Aono T, Minagawa J, Miyake A. Congenital malformations of newborn infants after clomiphene-induced ovulation. Fertil Steril 1983;40:187-9.
168. Mills JL, Simpson JL, Rhoads GG, Graubard BI, Hoffman H, Conley MR, et al. Risk of neural tube defects in relation to maternal fertility and fertility drug use. Lancet 1990;336:103-4.
169. Greenland S, Ackerman DL. Clomiphene citrate and neural tube defects: a pooled analysis of controlled epidemiologic studies and recommendations for future studies. Fertil Steril 1995;64:936-41.
170. James WH. Anencephaly, ovulation stimulation, subfertility, and illegitimacy (letter). Lancet 1973;2:916.
171. Butterworth CE, Tamura T. Folic acid safety and toxicity: a brief review. Am J Clin Nutr 1989;50:353-8.